• Site network leadership, business development, key accounts project delivery, participant recruitment/prescreening/retention, budgets/contracts/finance, legal, HR, corporate development, regulatory/study startup, technology, scientific affairs• Operations for over 300 FDA Phase I-IV clinical trials• Invited speaker at CTAD (2022), Society for Clinical Research Sites (2024), MAGI (2016-2020), ACRP (2017), Global Alzheimer's Platform (2018, 2019)

Consultant to Lilly regarding Donanemab, an anti-amyloid antibody being investigated for the treatment of early Alzheimer's Disease, as well as other neuroscience compounds and related studies. Advise on clinical research strategy, review of clinical data, and study design.

Consultant to Lilly regarding Biomedicines clinical trials. Scope includes providing feedback on protocol feasibility, clinical trial execution, recruitment and enrollment initiatives, and other clinical trial related research processes or innovation projects.

• Contributed to the development of technology solutions that create a more transparent, predictable clinical trial experience for study sponsors, by providing research site operation and workflow expertise• Contributed to the development of a novel site network dedicated to making clinical research a care option to every patient

Consultant to INC Research-sponsored Society of Clinical Research Sites Site Advocacy Group, providing expertise in clinical research Investigator Payments.